• Ongoing phase 1/2 study with up to 64 patients
  • The patients have received 1–4 earlier lines of therapy including IMiDs and PIs
  • Demonstrates how melflufen can be administered as a combination therapy with daratumumab or bortezomib
  • Explores potential for using melflufen in earlier lines of therapy
  • May significantly increase melflufen’s market potential as a combination therapy
  • Started in Q2 2018. The daratumumab arm is fully recruited while the recruitment to the bortezomib arm is expected to be completed in 2021. Recruitment to the bortezomib arm was temporarily paused during March-May 2020 due to the COVID-19 pandemic